59 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
3 Jun 24
Current report (foreign)
4:05pm
only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI® REMS Program.
WARNINGS AND PRECAUTIONS … under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI® REMS.
Further information is available at https://www.carvyktirems.com
6-K
EX-99.1
LEGN
Legend Biotech Corp
23 May 24
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
5:00pm
CARVYKTI ®.
CARVYKTI ® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI® REMS … is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI® REMS.
Further information
6-K
EX-99.1
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
growth strategy for good corporate citizenship
* In December 2017, Legend Biotech entered into an exclusive worldwide collaboration and license
6-K
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies
6-K
EX-99.1
LEGN
Legend Biotech Corp
22 Apr 24
Current report (foreign)
1:06pm
-cell immunotherapies, including CARVYKTI®.
CARVYKTI® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy … toxicities, CARVYKTI® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI® REMS
6-K
EX-99.1
vjtx69crkbmh
8 Apr 24
Current report (foreign)
7:03am
F-3ASR
m4botuq w53iwo06jl6t
19 Mar 24
Automatic shelf registration (foreign)
7:57am
6-K
EX-99.1
959hwboi
15 Mar 24
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study
3:18pm
6-K
EX-99.1
a8y3uovb2o7ao08tv
23 Feb 24
Current report (foreign)
7:16am
6-K
EX-99.1
5wu2lqisxo
9 Jan 24
Legend Biotech Corporation 6-K
4:01pm
6-K
EX-99.1
rxb6128k
11 Dec 23
Legend Biotech Corporation 6-K
7:32pm
6-K
c7oowmclkj52rc
20 Nov 23
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
6:02am
6-K
sbhjpzivdc
15 Aug 23
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
6:10am
6-K
EX-99.1
vkakcmgj144ve3guydh
6 Jun 23
Legend Biotech Corporation 6-K
4:44pm
6-K
EX-99.1
nk6sn gfn
5 Jun 23
Legend Biotech 6-K
11:17am
F-3ASR
l6z88b7h
26 May 23
Automatic shelf registration (foreign)
9:01am
6-K
EX-99.1
tey9ugsk 2v0mpmh4y3u
25 May 23
Legend Biotech Corporation 6-K
8:30am
6-K
EX-99.1
7ntfci886 wsbm
16 May 23
Legend Biotech Corporation 6-K
8:39am